Ascendis Pharma (NASDAQ:ASND) has outperformed the market over the past 5 years by 5.62% on an annua

COPENHAGEN, Denmark, Aug. 06, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today prov

Morgan Stanley analyst Maxwell Skor maintains Ascendis Pharma (NASDAQ:ASND) with a Overweight and

Crinetics Pharmaceuticals (NASDAQ:CRNX | CRNX Price Prediction) shares have climbed 99% just this we

RBC Capital analyst Luca Issi maintains Ascendis Pharma (NASDAQ:ASND) with a Outperform and raise

Let us begin with a midyear summary of index results that might surprise you in light of the triple-

COPENHAGEN, Denmark, June 30, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today anno

Ascendis Pharma A/S (NASDAQ:ASND) today announced that the Company has been added to the broad-marke

COPENHAGEN, Denmark, June 26, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today anno

Ascendis Pharma (ASND) witnessed a jump in share price last session on above-average trading volume.

COPENHAGEN, Denmark, June 25, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today anno

Multi-organ system and quality-of-life benefits sustained through three and a half years 86% respons

COPENHAGEN, Denmark, June 13, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today anno

Ascendis Pharma (ASND) stock rises after releasing impressive 5-year Phase 2 data for its hypoparath

The Touchstone Mid Cap Growth Fund (Class A Shares, Load Waived) outperformed its benchmark, the Rus

Ascendis Pharma A/S (NASDAQ:ASND) today announced 5-year (Week 266) data from its Phase 2 PaTH Forwa

– Multi-organ system and quality-of-life benefits sustained through five years of treatment – 82% re

COPENHAGEN, Denmark, June 08, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today anno

Ascendis Pharma is initiated with a buy rating, reflecting its transition to a durable, commercial-s

Citigroup analyst Eric Joseph initiates coverage on Ascendis Pharma (NASDAQ:ASND) with a Buy rati

Evercore ISI Group analyst Josh Schimmer maintains Ascendis Pharma (NASDAQ:ASND) with a Outperfor

Barclays analyst Eliana Merle maintains Ascendis Pharma (NASDAQ:ASND) with a Overweight and raise

Ascendis Pharma A/S (ASND) Q1 2026 Earnings Call Transcript

Wells Fargo analyst Derek Archila maintains Ascendis Pharma (NASDAQ:ASND) with a Overweight and l

Ascendis Pharma (NASDAQ:ASND) reported quarterly earnings of $0.32 per share which beat the analyst

- Q1 2026 revenue of €197 million for YORVIPATH ® and €44 million for SKYTROFA ® - More than 1,000 n

COPENHAGEN, Denmark, May 06, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today annou

COPENHAGEN, Denmark, April 30, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today ann

COPENHAGEN, Denmark, April 21, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today ann

Assetmark Inc. raised its holdings in Ascendis Pharma A/S (NASDAQ: ASND) by 48.1% in the undefined q

Ascendis Pharma A/S (NASDAQ:ASND) today announced the commencement of trading of its ordinary shares

COPENHAGEN, Denmark, April 20, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today ann

B of A Securities analyst Tazeen Ahmad maintains Ascendis Pharma (NASDAQ:ASND) with a Buy and rai

Wedbush analyst Yun Zhong reiterates Ascendis Pharma (NASDAQ:ASND) with a Outperform and maintain

 - Ordinary shares expected to commence trading on Nasdaq on April 20, 2026 following exchange of al

- Ordinary shares expected to commence trading on Nasdaq on April 20, 2026 following exchange of all

Ascendis Pharma A/S (NASDAQ:ASND) today announced that YUVIWEL (navepegritide; developed as TransCon

Ascendis Pharma A/S (Nasdaq: ASND) today announced positive Week 52 topline results from New InsiGHT

Ascendis Pharma A/S (NASDAQ:ASND) today announced new data from its pivotal ApproaCH Trial showing t

RBC Capital analyst Luca Issi maintains Ascendis Pharma (NASDAQ:ASND) with a Outperform and raise

Ascendis Pharma shares rise after FDA approves Yuviwel, a weekly treatment for children with achondr

The first and only approved achondroplasia therapy to provide continuous systemic exposure to CNP ov

BridgeBio stock rises after Phase 3 trial shows its drug helped children with achondroplasia grow fa

Oppenheimer analyst Leland Gershell maintains Ascendis Pharma (NASDAQ:ASND) with a Outperform and

Wedbush analyst Yun Zhong maintains Ascendis Pharma (NASDAQ:ASND) with a Outperform and raises th

Ascendis Pharma (NASDAQ:ASND) reported quarterly losses of $(0.64) per share which missed the analys

Amy Raskin, CIO at Chevy Chase Trust, named Ascendis Pharma (ASND) as her final trade on CNBC's